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Summary
Background: Recent	studies	report	 increased	risks	of	both	cancer	and	mortality	 in	
paediatric	onset	inflammatory	bowel	disease	(pIBD)	but	the	reproducibility	of	this	is	
unknown.
Aim: In	this	population‐based	study	we	aim	to	estimate	the	risk	of	cancer	and	mortal-
ity	in	the	Danish	and	Finnish	pIBD	population	in	a	23‐year	period	compared	to	the	
general	population.
Methods: The	pIBD	population	was	defined	as	individuals	registered	in	the	national	
patient	registries	with	a	diagnosis	of	Crohn's	disease	(CD),	ulcerative	colitis	(UC)	or	
IBD‐unclassified	before	their	18th	birthday	from	1992	to	2014.	This	cohort	was	cross	
referenced	with	the	national	cancer	and	mortality	registries	identifying	all	pIBD	pa-
tients	who	subsequently	developed	cancer	and/	or	died	and	followed	up	to	the	end	
of	 2014.	 Risk	 estimates	 are	 presented	 as	 standardised	 incidence	 ratios	 calculated	
based	on	incidence	figures	from	the	populations.
Results: Six	thousand	six	hundred	and	eight‐nine	patients	with	pIBD	were	identified	
(median	age	at	follow‐up	22.3	years;	median	follow‐up:	9.6	years	[interquartile	range:	
4.8‐16.0]).	Seventy‐two	subsequently	developed	cancer	and	65	died.	The	standard-
ised	incidence	ratio	of	cancer	in	general	was	2.6	(95%	CI:	1.8‐3.7)	and	2.5	(95%	CI:	
1.8‐3.4)	in	CD	and	UC,	respectively.	The	standardised	mortality	ratios	were	2.2	(95%	
CI:	1.4‐3.4)	and	3.7	(95%	CI:	2.7‐5.0)	in	CD	and	UC,	respectively.	The	leading	causes	
for	mortality	were	cancer,	suicide	and	infections.
Conclusions: We	found	an	increased	risk	of	cancer	and	mortality	in	pIBD.	This	under-
lines	 the	 importance	 of	 cancer	 surveillance	 programs	 and	 assessment	 of	 mental	
health	in	the	standard	of	care	in	adolescent	pIBD	patients.
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1  | INTRODUC TION
The	 incidence	of	 cancer	 and	mortality	 in	 IBD	has	been	extensively	
debated	 for	decades.	Recent	 results	 from	studies	 reporting	on	col-
orectal	cancers	(CRC),	also	termed	disease	associated	cancers,	are	in-
consistent	with	the	historical	literature,	reporting	lower	risk	estimates	
and	some	finding	no	increased	risk	of	cancer.1-4	The	reasons	for	this	
decline	in	incidence	is	unknown,	but	is	speculated	to	be	due	to	new	
treatment	modalities	and	colectomies	performed	at	an	earlier	stage.5,6
The	 few	 population‐based	 cancer	 studies	 that	 include	 su-
banalyses	 on	 paediatric	 onset	 IBD	 (pIBD)	 have	 found	 an	 overall	
two‐three	 fold	 increased	 risk	 of	 cancer.2,7,8	 In	 the	 paediatric	 lit-
erature	on	malignancy	in	IBD,	only	two	population‐based	studies	
exist.	One	of	 these	reported	a	25‐fold	 increase	 in	CRC	 in	paedi-
atric	 onset	 ulcerative	 colitis	 (pUC),	 but	 this	 study	 included	 only	
69	 patients	 of	whom	 two	 developed	CRC.9	 The	 last	 and	 largest	
study	 in	 pIBD,	 a	 nation‐wide	 study	 from	Sweden,	 demonstrated	
a	 twofold	 increase	 in	cancer	 in	general	and	a	18‐fold	 increase	 in	
gastro‐intestinal	cancers.10
Regarding	mortality,	the	risk	of	death	in	IBD	seems	to	be	declin-
ing,	 especially	 in	UC.	However,	 compared	 to	 the	general	 popula-
tion,	there	is	an	increased	risk	of	mortality	in	both	CD	and	UC.11 In 
pIBD	knowledge	is	sparse	regarding	the	risk	and	causes	of	mortal-
ity.	Joosse	et	al	published	a	3‐year	prospective	study	in	2018	from	
multiple	 centres	 in	 Europe.12	 They	 reported	 26	 deaths	 with	 the	
main	causes	of	mortality	being	cancer	and	infections.	Later	in	2018,	
Olén	et	al	published	a	nation‐wide	study	from	Sweden,	which	is	to	
date	the	largest	study	regarding	this	topic.13	They	found	a	fourfold	
increase	in	the	risk	of	mortality	in	pUC	and	a	twofold	risk	in	paedi-
atric	onset	CD	(pCD)	with	the	main	cause	of	mortality	being	cancer.
Based	on	these	observations	it	seems	plausible	that	pIBD	is	an	
important	risk	factor	of	both	cancer	and	mortality	in	both	late	ado-
lescent	and	early	adulthood.	However,	our	knowledge	on	this	sub-
ject	 is	 primarily	 derived	 from	 studies	 performed	 in	 a	 single	 study	
cohort	(the	two	nationwide	Swedish	studies10,13).	Hence,	we	aim	to	
estimate	the	risk	of	cancer	and	mortality	in	pIBD	diagnosed	in	two	
more	 recent	 nationwide	 population‐based	 cohorts	 from	Denmark	
and Finland.
2  | MATERIAL S AND METHODS
2.1 | Study design
In	this	population‐based	retrospective	registry	study	we	included	all	
patients	diagnosed	with	pIBD	in	Denmark	and	Finland	in	the	period	
from	1	January	1992	 to	31	December	2014.	PIBD	was	defined	as	
patients	who	were	diagnosed	with	IBD	before	their	18th	birthday.	
The	pIBD	cohort	was	crosslinked	(through	a	unique	social	security	
number	given	to	all	citizens	in	both	Denmark	and	Finland)	to	the	na-
tional	 cancer	 registries	 and	 the	national	 cause	of	 death	 registries,	
where	patients	who	developed	cancer	(any)	or	died	after	their	IBD	
diagnosis	were	identified.
2.2 | Study population
In	 both	 Danish	 and	 Finnish	 registries,	 IBD	 was	 defined	 as	
International	Classification	of	Diseases	eight	revision	(ICD‐8)	codes	
56300‐56309,	 ninth	 revision	 (ICD‐9)	 code	 555	 or	 tenth	 revision	
(ICD‐10)	code	group	K50	or	ICD‐8	code	56319,	ICD‐9	code	556	or	
ICD‐10	code	group	K51.
In	Denmark,	the	pIBD	cohort	was	identified	through	the	Danish	
National	Patient	Registry	(LPR),	which	contains	information	of	inpa-
tient	hospitalisation	from	1977	and	outpatient	contacts	from	1994.	
We	considered	 the	diagnosis	 as	 valid	 if	 two	or	more	entries	were	
made	with	an	 IBD	diagnosis,	 as	 this	has	previously	been	 found	 to	
ensure	the	validity.14	Data	regarding	surgery	(colectomy)	were	also	
collected	through	the	LPR.	The	Danish	pIBD	cohort	was	crosslinked	
to	 the	Danish	Cancer	Registry	and	Causes	of	Death	Registry.	The	
Danish	Cancer	Registry	contains	data	on	all	patients	diagnosed	with	
any	 cancer	 in	 Denmark	 (including	 exact	 diagnosis	 and	 date	 of	 di-
agnosis).	 The	Causes	of	Death	Registry	 contains	data	on	 cause	of	
and	time	of	death.	To	verify	both	the	IBD	and	the	cancer	diagnosis,	
we	crosslinked	cancer	cases	and	deaths	with	the	Danish	Pathology	
Database.
In	Finland,	 the	pIBD	cohort	was	 identified	 through	 the	Special	
Reimbursement	Registry	which	is	maintained	by	the	Social	Insurance	
Institution	of	Finland.	This	registry	includes	data	on	diagnosis	of	all	
patients	 eligible	 for	 special	 reimbursement	 of	 medical	 expenses,	
including	 IBD.	This	 registry	has	previously	been	shown	 to	have	an	
excellent	coverage	and	validity	and	has	been	used	 to	estimate	 the	
incidence	of	pIBD	in	Finland.15-17	The	pIBD	cohort	was	crosslinked	
to	the	National	 Institute	for	Health	and	Welfare	 (THL),	 the	Cancer	
Registry	 and	 the	 Causes	 of	 Death	 Registry.	 The	 Cancer	 Registry	
contains	data	on	all	patients	diagnosed	with	any	cancer	 in	Finland	
(including	exact	diagnosis	and	date	of	diagnosis).18,19	The	Causes	of	
Death	Registry	are	maintained	by	Statistics	Finland	and	contains	data	
on	the	cause	of	and	time	of	death.	To	assess	time	at	risk	of	colorectal	
cancer	the	pIBD	cohort	was	crosslinked	with	the	Care	Registry	for	
Health	Care	 (HILMO),	which	contains	data	on	all	surgical	 interven-
tions	in	Finland.
In	both	countries,	we	used	 the	 last	 recorded	diagnosis	code	 in	
the	 registries	 as	 the	 valid	 diagnosis.	 The	 age‐specific	 cancer	 rates	
in	 the	general	population	 for	each	country	were	derived	 from	 the	
NORDCAN	homepage,	where	cancer	incidences	in	the	Nordic	coun-
tries	are	published.20	In	both	Denmark	and	Finland,	the	age‐specific	
and	sex	specific	number	of	deaths	in	each	calendar	year	are	accessi-
ble	online	(www.dst.dk	and	www.stat.fi).
2.3 | Statistical analysis
For	cancer	and	mortality	analyses,	 the	number	of	person‐years	of	
follow‐up	was	calculated	from	the	date	of	 IBD	diagnosis	to	cancer	
diagnosis	 or	 death	 on	 31	December	 2014,	whichever	 event	 came	
first.	When	 estimating	 the	 risk	 of	 CRC,	 only	 person‐years	 before	
colectomy	were	considered	time	at	risk.
     |  3MALHAM et AL.
The	overall	differences	 in	cancer	and	mortality	 risks	between	
the	 pIBD	 cohorts	 and	 the	 general	 population	 were	 calculated	
using	 standardised	 incidence	 ratios	 (SIR)	 and	 standardised	 mor-
tality	ratios	(SMR).	Among	the	pIBD	patients,	the	numbers	of	ob-
served	cases	and	person‐years	at	risk	were	calculated	by	sex	and	
5‐year	 age	 groups.	 Analyses	were	 also	 performed	 separately	 for	
CD	and	UC.	The	expected	numbers	of	cases	for	total	cancers,	spe-
cific	cancer	sites,	all‐cause	mortality	and	cause‐specific	mortality	
were	calculated	by	multiplying	the	person‐years	at	risk	by	the	 in-
cidence	rates	of	each	cancer/	mortality	in	the	respective	sex,	age	
and	calendar	period	 in	 the	background	population	of	 the	 respec-
tive	 countries.	To	 calculate	SIR	or	SMR,	 the	observed	number	of	
cases	was	divided	by	the	expected	number.	For	SIR	and	SMR,	the	
exact	 95%	 confidence	 intervals	 (CI)	were	 calculated	 by	 assuming	
that	the	number	of	observed	cancer	and	mortality	cases	followed	a	
Poisson's	distribution.
Statistical	 analyses	were	performed	using	SAS	Enterprise	 (ver-
sion	7.11,	SAS	institute	Inc,	Cary.	NC.	USA).	The	study	was	approved	
by	the	Danish	Patient	Safety	Authority.	As	the	study	did	not	involve	
direct	patient	contact	ethical	approval	is	not	applicable	according	to	
legislation	in	neither	Denmark	nor	Finland.
3  | RESULTS
From	1992	 to	 2015	we	 identified	 6,689	 patients	with	 pIBD.	Of	
these,	3333	where	 identified	 in	Denmark	and	3357	were	 identi-
fied	 in	Finland.	The	median	age	at	 IBD	diagnosis	was	14.0	years	
(Interquartile	 range	 (IQR):	12‐16)	and	the	median	follow‐up	time	
was	9.6	years	IQR	4.8‐16.0.	The	background	population	in	the	cor-
respondent	age	groups	was	5	416	763	(2	517	198	and	2	899	565	
in	Denmark	and	Finland,	respectively).	The	baseline	demographics	
are	presented	in	Table	1	with	the	country	specific	demographics	
presented	 in	 Table	 S1.	 Total	 follow‐up	 time	 of	 the	 pIBD	 cohort	
was	71	675	person‐years,	with	37	830	person‐years	 in	Denmark	
(18	467	CD/	 19	 284	UC/	 79	 IBDU)	 and	 33	845	 person‐years	 in	
Finland	(12	746	CD/	20	860	UC/	239	IBDU).	When	combining	the	
two	cohorts,	the	median	age	at	end	of	follow‐up	was	22.3	years	
(IQR:17.4‐28.4)	(CD	22.4	years	[IQR:	17.4‐28.4]	and	UC	22.2	years	
[IQR:	17.8‐28.4]).	In	the	combined	pIBD	cohort,	720	patients	had	
a	 total	 colectomy	performed	with	a	median	 time	 from	diagnosis	
to	colectomy	of	2.8	years	(IQR:	1.0‐6.1).	A	total	of	1,365	patients	
(20.4%)	 underwent	 bowel	 resection	 (including	 colectomy)	 dur-
ing	follow‐up	(median	time	from	diagnosis	to	resection	2.6	years	
[IQR:	0.7‐6.1]).
3.1 | Cancer
Seventy‐two	cancer	cases	were	observed	in	the	pIBD	cohort	(38	
and	34	 in	Denmark	 and	Finland,	 respectively)	with	 an	 incidence	
rate	of	10/	10	000	person‐years	and	a	SIR	of	2.5	(95%	CI:	2.0‐3.2).	
The	characteristics	of	 the	cancer	cases	are	presented	 in	Table	2	
and	the	country	specific	characteristics	are	presented	in	Table	S2.	
Median	age	at	cancer	diagnosis	was	25.0	years	(range:	13‐35).	The	
risk	of	cancer	(any)	was	9.0/	10	000,	10.6/	10	000,	34.7/	10	000	
and	75.8/	10	000	patients	after	1,	5,	10	and	20	years	of	follow‐up,	
respectively.
In	 CD,	 the	 overall	 cancer	 incidence	was	 10.7/	 10	000	 person‐
years	 and	 the	 SIR	was	 2.6	 (CI:	 1.8‐3.7).	 The	 country	 specific	 inci-
dence	 rates	 were	 12.5/	 10	000	 and	 7.8	 /10	000	 patient	 years	 in	
Denmark	and	Finland,	respectively.	The	median	time	from	IBD	diag-
nosis	to	cancer	was	11.2	years	(range:	0.04‐19.3).
In	UC,	the	overall	cancer	incidence	was	9.7/	10	000	patient	years	
and	the	SIR	was	2.5	(CI:	1.8‐3.4).	The	country	specific	incidence	rates	
TA B L E  1  Baseline	characteristics	(including	cancer	and	
mortality	cases)	in	a	Danish	and	Finnish	paediatric	IBD	cohort	
diagnosed	1992‐2014	and	followed	up	to	the	end	of	2014
IBD‐total CD UC
Patients	(n)
Total 6689 2921 3741
Male 3544 1648 1882
Female 3145 1273 1859
Median	age	at	IBD	
diagnosis	(y	[IQR])
14.0	(12‐16) 14.0	(12‐16) 14.0	(11‐16)
Median	follow‐up	
time	(y	[IQR])
9.6	(4.8‐16.0) 9.5 
(4.8‐16.0)
9.8 
(4.8‐16.0)
Cancer	cases	(n) 72 33 39
Deaths	(n) 65 21 44
CD,	Crohn's	disease;	IBD,	inflammatory	bowel	disease;	IQR,	interquartile	
range;	UC,	ulcerative	colitis.
TA B L E  2  Number	and	age	of	cancer	and	mortality	cases	in	a	
Danish	and	Finnish	paediatric	IBD	cohort	diagnosed	1992‐2014	and	
followed	up	to	the	end	of	2014
IBD‐total CD UC
Cancer
Patients	(n)
Total 72 33 39
Male 37 15 22
Female 35 18 17
Median	age	at	
cancer 
diagnosis	
(y	[range])
25.0	(13‐35) 24.0	(15‐35) 25.0	(13‐33)
Mortality
Patients	(n)
Total 65 21 44
Male 39 16 23
Female 26 5 21
Median	age	at	
mortality 
(y	[range])
22.0	(8‐36) 24.0	(8‐36) 22.0	(14‐34)
CD,	 Crohn's	 disease;	 IBD,	 inflammatory	 bowel	 disease;	 UC,	 ulcerative	
colitis.
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were	 7.8/	 10	000	 and	 11.5/	 10	000	 patient	 years	 in	 Denmark	 and	
Finland,	respectively.	The	cancer	specific	SIRs	are	presented	in	Table	3	
and	the	country	specific	SIRs	are	presented	in	Table	S3.	The	median	
time	from	IBD	diagnosis	to	cancer	was	11.5	years	(range:	0.06‐21.2).
3.2 | Mortality
Of	 the	patients	 in	 the	pIBD	cohort	a	 total	of	65	patients	died,	29	
in	Denmark	and	36	in	Finland.	The	characteristics	of	the	mortality	
cases	are	presented	in	Table	2	with	the	country	specific	characteris-
tics	presented	in	Table	S2.	The	incidence	rate	of	mortality	was	9.1/	
10	000	patient	years,	with	an	incidence	rate	of	7.7	/10	000	patient	
years	 in	Denmark	 and	 10.6/	 10	000	 patient	 years	 in	 Finland.	 The	
overall	 (all	cause)	SMR	was	3.0	 (CI:	2.4‐3.9)	and	the	cause	specific	
mortalities	are	presented	in	Table	4	with	the	country	specific	mor-
talities	 presented	 in	 Table	 S4.	 The	median	 time	 from	diagnosis	 to	
mortality	 was	 9.4	years	 (range:	 0.01‐22.4)	 and	 the	 median	 age	
at	 mortality	 was	 22.0	years	 (range:	 8‐35).	 The	 leading	 causes	 of	
mortality	were	 cancer	 (one	 in	4008	patient	 years),	 suicide	 (one	 in	
4509	patient	 years)	 and	 infections	 (one	 in	6558	patient	 years).	As	
neither	Denmark	nor	Finland	have	age	matched	mortality	rates	avail-
able	on	the	exact	same	causes	of	deaths	as	found	in	our	study	(ex-
cept	suicide),	only	suicide	SMR	can	be	calculated,	which	is	presented	
in	Table	4.	Of	the	12	patients	who	died	due	to	infections,	six	patients	
had	a	sepsis	diagnosis	as	the	primary	cause	of	death.	Of	these,	one	
had	a	central	venous	catheter	infection,	one	had	peritonitis	from	a	
spontaneous	perforated	colon,	one	had	toxic	mega‐colon,	one	had	
streptococcal	sepsis	and	two	had	sepsis	of	unknown	origin.	The	re-
maining	six	patients	died	from	pneumonia	(n	=	5)	and	meningococcal	
meningitis	(n	=	1).
4  | DISCUSSION
In	 this	 nationwide	 population‐based	 study	 from	 Denmark	 and	
Finland,	we	 followed	 pIBD	 patients	 from	 IBD	 diagnosis	 to	 cancer	
TA B L E  3  Standardised	incidence	ratios	of	the	main	cancer	groups	and	the	number	of	specific	cancer	diagnoses	in	a	Danish	and	Finnish	
paediatric	IBD	cohort	diagnosed	1992‐2014	and	followed	up	to	the	end	of	2014
IBD‐total CD UC
Standardised	incidence	ratios	(95%	CI)
All 2.5	(2.0‐3.2) 2.6	(1.8‐3.7) 2.5	(1.8‐3.4)
Colorectal	cancers 15.3	(8.7‐24.8) 8.4	(2.3‐21.4) 21.4	(11.0‐37.4)
Small	bowel	cancers 21.8	(4.4‐63.6) 32.6	(3.7‐117.8) 13.3	(0.2‐74)
Liver	cancers 42.8	(19.5‐81.3) 21.8	(2.5‐78.9) 59.5	(23.8‐122.6)
Lymphomas 2.9	(1.4‐5.3) 3.2	(1.0‐7.6) 2.6	(0.8‐6.0)
Skin	cancers 4.2	(2.4‐6.7) 6.7	(3.4‐11.6) 2.2	(0.7‐5.2)
Number	of	cancer	cases	(n)
Gastrointestinal
Colorectal	cancer 16 4 12
Small	bowel	cancer 3 2 1
Liver	cancers
Cholangiocarcinoma 8 1 7
Hepatocellular	carcinoma 1 1 0
Lymphomas
Hodgkin's	lymphoma 7 4 3
Non‐Hodgkin's	lymphoma 3 1 2
Skin	cancer
Malignant	melanoma 10 7 3
Basal	cell	carcinoma 7 5 2
Non‐IBD	related	cancers
Genital	cancers 6 4 2
Sarcoma 3 1 2
Adrenal	tumour 1 0 1
Mucoepidermoid	carcinoma 1 1 0
Haematologic	cancers 2 1 1
CNS	tumour 4 2 2
CD,	Crohn's	disease;	CI,	confidence	interval;	IBD,	inflammatory	bowel	disease;	UC,	ulcerative	colitis.
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diagnosis	or	mortality	and	found	an	increased	risk	of	both	cancer	and	
mortality	in	patients	with	paediatric	onset	of	IBD	compared	to	the	
general	population.	The	increased	risk	of	cancer	was	mainly	due	to	
an	 increased	frequency	of	colorectal	adenocarcinomas	 (CRC),	 liver	
cancers,	skin	cancers	and	lymphomas	and	the	median	age	of	cancer	
diagnosis	was	 25	years.	 The	 three	most	 common	 causes	 of	 death	
were	cancer,	suicide	and	infections	and	the	median	age	of	mortality	
was	22	years.
We	found	a	2.5‐fold	increase	in	the	risk	of	cancer	in	pIBD	com-
pared	to	the	general	population	with	identical	risk	estimates	in	CD	
and	UC.	This	is	almost	identical	to	the	increased	risk	estimate	found	
in	 the	 recent	nationwide	Swedish	pIBD	study10	 and	 twice	 the	 risk	
estimate	 reported	 in	 the	 recent	adult	 literature.7,21	 In	 the	Swedish	
study	 they,	however,	 reported	an	almost	20‐fold	 increased	 risk	of	
developing	CRC	which	is	higher	than	the	15‐fold	increased	risk	re-
ported	 in	our	 study.	Most	 studies	 reporting	on	CRC	 in	pIBD	have	
reported	higher	risk	estimates	of	CRC	than	we	found.1,9,21,22	Many	of	
the	previous	studies,	including	the	Swedish	study,	included	historical	
patient	cohorts	dating	back	before	the	1980s.	As	some	adult	studies	
have	shown	a	decreasing	risk	of	CRC	over	the	last	decades,1,4 we be-
lieve	that	the	results	presented	in	this	paper	more	accurately	reflects	
the	actual	risk	of	developing	CRC	for	pIBD	patients	diagnosed	within	
the	past	10‐20	years	which	is	seven	times	the	risk	estimate	of	CRC	in	
the	adult	population.2	We	also	found	a	very	high	risk	of	liver	cancer,	
mainly	cholangiocarcinomas	in	UC	patients.	In	a	primary	sclerosing	
cholangitis	 (PSC)	cohort	 from	Sweden,	 in	which	79%	had	 IBD,	 the	
risk	of	cholangiocarcinoma	was	reported	to	be	160‐fold	increased,	
compared	with	 the	general	population.23	 It	could	 therefore	be	hy-
pothesised,	that	the	increased	risk	of	cholangiocarcinoma	reported	
in	our	study	can	be	attributed	solely	to	PSC.	This	study	was	not	de-
signed	to	evaluate	concomitant	PSC.	However,	in	the	Danish	popula-
tion,	the	data	extract	did	allow	for	a	post	hoc	analysis	of	concomitant	
PSC.	A	PSC	diagnosis	was	only	found	in	one	of	the	six	patients	devel-
oping	cholangiocarcinoma.	Hence,	it	seems	that	the	pIBD	diagnosis	
increases	the	risk	of	liver	cancer.
We	 found	 three	 cases	 of	 small	 bowel	 carcinomas	 (SBC)	 in	 the	
Finnish	 population	 (age	 at	 cancer	 diagnosis:	 22‐33	years.	 Year	 of	
diagnosis:	2003‐2014).	The	 risk	of	SBC	has	also	been	 found	 to	be	
increased	 in	 coeliac	disease,24	which	may	be	 associated	with	 IBD.	
Hence,	it	remains	unknown	if	the	increased	SIR	of	SBC	is	explained	
by	pIBD.	The	 fact,	 that	one	of	 the	 three	SBC's	developed	 in	a	UC	
patient,	who	should	have	no	inflammation	in	the	short	bowels,	sup-
ports	the	hypothesis	that	the	SBC	might	also	depend	on	other	fac-
tors	than	pIBD.
Due	 to	 the	 immunosuppressant	 effects	 of	 both	 immunomod-
ulators	 and	 biologicals,	 IBD	 patients	 are	 considered	 to	 be	 at	 an	
increased	 risk	 of	 lymphoproliferative	 diseases	 (primarily	 lympho-
mas).25	 Two	 tertiary	 centre	 studies	 found	 that	 pIBD	 patients	 had	
an	 increased	 risk	 lymphoproliferative	 diseases	 when	 treated	 with	
thiopurines.26,27	The	only	population‐based	study	report	on	lymph-
oproliferative	diseases	 in	pIBD	found	a	2.7	times	 increased	risk	of	
developing	 lymphoproliferative	 diseases,10	 which	 is	 similar	 to	 the	
risk	estimates	reported	in	our	study.	When	stratifying	by	IBD	diag-
nosis,	only	CD	had	a	significantly	increased	risk	with	a	SIR	of	3.2.	As	
thiopurines	are	standard	treatment	of	pCD	in	Denmark	and	Finland	
and	have	been	so	since	the	late	1990s,28	it	is	likely	that	the	CD	pa-
tients	affected	had	been	treated	with	thiopurines.	However,	due	to	
the	design	of	this	study,	we	cannot	elaborate	on	the	risk	factor	of	
thiopurines	in	developing	lymphoproliferative	diseases	(or	any	other	
cancer).
An	increased	risk	of	skin	cancer	has	previously	been	reported	in	
IBD.	Our	risk	estimate	is	in	line	with	the	Swedish	nationwide	study10 
but	significantly	higher	than	the	estimates	previous	reported	in	adult	
IBD	cohorts.7,21	In	our	study,	the	increased	risk	of	skin	cancer	was	
restricted	to	CD	patients	(SIR	6.7),	which	was	also	found	in	the	pre-
vious	studies.	Skin	cancers,	especially	nonmelanoma,	have	been	at-
tributed	to	thiopurine	treatment.	A	recent	meta‐analysis,	 including	
mainly	adult	studies,	found	that	thiopurine	treatment	increased	the	
risk	of	nonmelanoma	skin	cancer	by	2.8.29	However,	as	with	lymph-
oproliferative	disease,	our	study	design	does	not	allow	further	elab-
oration	of	treatment	exposures	effect	on	cancer	risk.
We	 found	 a	 threefold	 increase	 in	 the	 standardised	 mortal-
ity	 ratio,	with	 the	peak	 incidence	 rate	 in	UC	 (SMR	3.7),	which	 is	a	
threefold	increase	compared	to	results	published	in	the	aIBD	popu-
lation.11	This	is	in	line	with	a	recent	nationwide	study	from	Sweden13 
were	the	main	mortality	causes	 (by	number	of	cases)	were	cancer,	
gastrointestinal	causes	and	trauma.	Unexpectedly,	in	both	Denmark	
and	Finland,	 suicide	was	among	 the	 leading	causes	of	mortality	 in	
our	study.	This	was	not	reported	in	the	Swedish	study	and	may	re-
flect	a	limitation	in	registry‐based	studies.	We	found	the	death	rate	
due	to	suicide	increased	(SMR	4.0)	compared	to	the	general	popu-
lation.	This	has	not	previously	been	shown,	but	it	may	be	due	to	the	
decreased	quality	of	life	and	increased	risk	of	depressive	disorders	in	
pIBD	previously	described.30,31
The	other	 important	cause	of	mortality	 (besides	cancer)	 in	our	
study,	 was	 infections.	 This	 is	 in	 line	 with	 two	 previous	 European	
multicentre	 studies	 and	 a	 systematic	 review	 reporting	 on	 cancer	
and	mortality	in	pIBD.12,32,33	However,	these	studies	where	mainly	
TA B L E  4  Standardised	mortality	ratios	and	the	number	of	
specific	mortality	causes	in	a	Danish	and	Finnish	paediatric	IBD	
cohort	diagnosed	1992‐2014	and	followed	up	to	the	end	of	2014
IBD‐total CD UC
Standardised	mortality	ratios	(95%	CI)
All 3.0	(2.4‐3.9) 2.2	(1.4‐3.4) 3.7	(2.7‐5.0)
Suicide 3.8	(2.2‐6.0) 2.8	(1.0‐6.2) 4.6	(2.4‐8.0)
Cause	specific	mortality	(n)
Cancer 18 3 15
Infections 11 3 8
Suicide 18 6 12
Gastrointestinal 2 2 0
Other 16 7 9
CD,	Crohn's	 disease;	CI,	 confidence	 interval;	 IBD,	 inflammatory	bowel	
disease;	UC,	ulcerative	colitis.
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case	based	and	 the	 systematic	 review	 is	primarily	based	on	 those	
two	studies.
The	strength	of	 this	study	 is	 the	nationwide	design	with	 inclu-
sion	of	 recent	pIBD	patients	 in	both	Denmark	 and	Finland,	which	
resulted	 in	a	sufficient	sample	size	without	 including	historical	pa-
tients.	The	national	patient	 registries	have	previously	been	shown	
to	have	excellent	coverage.14‐16	In	Denmark,	the	LPR	did	not	include	
outpatients	until	 1994.	However,	 patients	diagnosed	with	pIBD	 in	
Denmark	are	almost	exclusively	diagnosed	by	endoscopy,	which	 is	
an	 inpatient	procedure	(included	in	the	LPR	since	1977),	and	pIBD	
patients,	given	its	aggressive	nature,34,35	will	require	long‐term	care	
in	the	outpatients	clinic	and,	hence,	also	be	included	in	the	LPR	be-
fore	1992.	 In	Denmark,	all	cancer	cases	were	verified	through	the	
national	pathology	database,	which,	by	law,	 includes	pathology	re-
ports	 from	 all	 cancer	 patients	 in	Denmark.	 In	 Finland,	 the	 cancer	
registry	has	previously	been	shown	 to	have	an	excellent	coverage	
with	over	98%	of	all	cancers.18,19	As	the	hospitals	in	both	Denmark	
and	Finland	are	mainly	government	driven	and	all	major	expenses	
to	medicine	is	deductible,	the	fact	that	this	study	included	patients	
from	both	Denmark	and	Finland	 is	not	perceived	as	 a	problem	by	
the	authors,	as	patients	in	both	countries	had	similar	access	to	both	
immunomodulators,	biologicals	and	surgery,	if	needed.	Despite	the	
previously	proven	validity	of	the	Danish	and	Finnish	registries,	the	
main	weakness	of	the	present	study	 is	the	retrospective	nature	of	
the	study	and	the	fact	that	we	relied	solely	on	registry	data	with	no	
possibility	 to	 verify	 the	 data	 in	 patient	 charts.	However,	with	 the	
previously	 proven	 excellent	 coverage,	we	 do	 not	 believe	 that	 this	
has	flawed	the	reported	results	in	this	study.	Lastly,	the	registries	did	
not	allow	us	to	elaborate	on	disease	severity,	disease	localisation	or	
treatment	exposures	as	risk	factors	of	cancer	or	mortality.
In	conclusion,	we	found	an	 increased	risk	of	both	cancer	and	
mortality	 in	 pIBD	with	 cancer	 presentation	 from	 the	 late	 teens	
and	early	adulthood.	This	adds	to	the	mounting	evidence34‐36	that	
pIBD	 is	 a	 distinct	 IBD	 phenotype	 and	 should	 be	 appreciated	 as	
a	 disease	 modifier	 predicting	 a	 more	 aggressive	 disease	 course	
compared	 to	adult	onset	 IBD.	Moreover,	 the	number	of	 suicides	
was	 alarming,	 warranting	 attention	 to	 the	 mental	 health	 of	 the	
patients.	Lastly,	 this	study	highlights	 the	need	for	 future	studies	
designed	to	estimate	possible	risk	factors	of	cancer	development	
in	pIBD.	This	would	facilitate	the	design	of	an	evidence‐based	can-
cer	 surveillance	 program	 in	 pIBD	 patients	 which,	 in	 the	 light	 of	
the	present	findings,	appears	to	be	needed	in	the	standard	care	of	
adolescent	pIBD	patients.
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